| ID | 1101 |
| Name of the vaccine | Dukoral |
| Microbe | Bacteria |
| Disease name | Cholera |
| Name of bacteria | Vibrio cholerae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | From 2 years |
| Description of the vaccine | Oral cholera vaccine (OCVs) used mainly by travellers. In February 2015, Dukoral was acquired by Valneva, Lyon, France. |
| Name of the manufacturer | SBL Vaccines |
| Name of the manufacturing country | Sweden |
| Year of manufacture | 1980 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | Short-term protective efficacy after 2 doses was 85% and 60.5% for the booster dose. |
| Vaccine formulation | Suspension
|
| Dosage | Primary vaccination: Two doses and children aged 2 -5 require a third dose, Booster vaccination: Single dose. |
| Mechanism of action | Bacterial strains of both Inaba and Ogawa serotypes and of El Tor and classical biotypes are included in the vaccine. It acts by inducing antibodies against both
the bacterial components and CTB. |
| Route of administration | Oral |
| Indications | Immunisation does not protect against V. cholerae serogroup O139 or other species of Vibrio. |
| Export | Marketing Authorisation Holder: SBL Vaccines, Sweden |
| Approval | WHO prequalified (2001) and EMA (2004) |
| Adjuvant | NA |
| Repurposing | Short-term protection against enterotoxigenic E. coli (ETEC). |
| Side effects of vaccine | Abdominal pain, diarrhoea, loose stools, nausea and vomiting. |
| Post vaccination | Food, drink and oral administration of other vaccines should be avoided 1 hour before and after vaccination. |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 31879125 |
| Clinical trial number | NA |
| Reference | https://ec.europa.eu/health/documents/community-register/2009/2009032555648/anx_55648_en.pdf |
| Other name | NA |
| Additional Links | https://www.who.int/news-room/fact-sheets/detail/cholera
|